<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="glofitamab-salvage-rrdlbcl-huang-ps1963">
    <meta name="study:title" content="PS1963 - Glofitamab + salvage therapy in R/R DLBCL (Real-World)">
    <meta name="study:fileName" content="Abstracts/PS1963-Glofitamab-Salvage-RRDLBCL-Huang.html">
    <meta name="study:cancerTypes" content="DLBCL,HGBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Glofitamab,Bispecific antibodies,Obinutuzumab,Monoclonal Antibody,Rituximab,Chemotherapy,CIT,DHAP,GemOx,EPOCH">

    <title>PS1963: Glofitamab + Salvage Tx in R/R DLBCL (Huang) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1963 - Glofitamab + Salvage Therapy in R/R DLBCL (Real-World, China)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=42)</h4>
                    <p>R/R DLBCL Pts (high-risk, Chinese). Aim: Evaluate efficacy & safety of Glofitamab + salvage chemo.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 64 64" fill="var(--sobi-teal)">
                        <path d="M32 60 V40 M20 40 L32 40 L44 40 M20 40 L12 28 L4 20 M44 40 L52 28 L60 20 M12 28 L16 24 M52 28 L48 24" stroke="var(--sobi-teal)" stroke-width="5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
                        <circle cx="4" cy="20" r="3" fill="var(--sobi-orange)"/><circle cx="60" cy="20" r="3" fill="var(--sobi-yellow)"/>
                    </svg>
                    <h4>Intervention</h4>
                    <p>Glofitamab (step-up) + salvage chemo (DHAP, GemOx, EPOCH, etc.). Obi pre-tx. Prospective study.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (DLBCL, N=36 Evaluable)</h4>
                    <p>ORR: <span class="highlight-value">72.2%</span>, CRR: <span class="highlight-value">38.8%</span>. All CRs ongoing. mOS/mPFS not reached.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Effective & safe. CRS 90.5% (G1 80.1%). G3/4 Neutropenia 54.8%. No G5 AEs. Promising for high-risk R/R DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1963 - Glofitamab combined with salvage therapy for relapsed or refractory diffuse large B cell lymphoma: A real-world prospective observational study in Chinese patients</h1>
            <p class="abstract-sub-header">Haiwen Huang, Jin Zhou, Tao You</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1963 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Glofitamab, a CD20xCD3 bispecific antibody, has shown remarkable effectiveness in R/R DLBCL in clinical trials (e.g., NCT03075696), leading to high CR rates and durable responses.</li>
                        <li>Real-world data on glofitamab, especially in combination with salvage therapies for high-risk patients, is limited.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To explore the efficacy and safety of Glofitamab combined with salvage therapy in Chinese patients with R/R DLBCL in a real-world setting through a prospective observational study.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Real-world prospective observational study (NCT06497452). Approved by IRB (20240430041615581).</li>
                        <li>Patient Population: R/R DLBCL patients aged ≥18 years.</li>
                        <li>Intervention: Glofitamab combined with salvage therapy (e.g., DHAP, GemOx, EPOCH regimen).
                            <ul class="list-circle list-inside ml-4">
                                <li>Obinutuzumab 1000mg IV on Cycle 1 Day 1 (C1D1) as pretreatment.</li>
                                <li>Glofitamab step-up dosing: C1D8 (2.5mg), C1D15 (10mg).</li>
                                <li>Glofitamab full dose: 30mg from C2D1.</li>
                                <li>Salvage therapy given at standard dose per protocol.</li>
                            </ul>
                        </li>
                        <li>Assessments: Safety evaluated each cycle. Efficacy by PET-CT at screening and every two cycles.</li>
                        <li>Data Cutoff: December 1, 2024.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Study Flow: Glofitamab + Salvage Therapy</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=42)</strong>
                            <span>R/R DLBCL, Age ≥18 years</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-blue-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Treatment Regimen</strong>
                                <span>Obinutuzumab Pretreatment (C1D1)</span>
                                <span>Glofitamab Step-up (C1D8: 2.5mg, C1D15: 10mg)</span>
                                <span>Glofitamab Full Dose (C2D1+: 30mg)</span>
                                <span>+ Standard Salvage Chemotherapy (DHAP, GemOx, EPOCH, etc.)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Safety (Each Cycle)</span>
                           <span>Efficacy (PET-CT q2 Cycles)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=42)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>52 (18-86)</td></tr>
                                <tr><td>Female, n (%)</td><td>26 (61.9%)</td></tr>
                                <tr><td>Male, n (%)</td><td>16 (38.1%)</td></tr>
                                <tr><td>IPI Score ≥3, n (%)</td><td>42 (100%)</td></tr>
                                <tr><td>Ann Arbor Stage III/IV, n (%)</td><td>42 (100%)</td></tr>
                                <tr><td>Pathologic Types, n</td><td></td></tr>
                                <tr><td class="pl-4">DLBCL</td><td>40</td></tr>
                                <tr><td class="pl-4">Burkitt's lymphoma</td><td>1</td></tr>
                                <tr><td class="pl-4">High-grade B-cell lymphoma (HGBCL)</td><td>1</td></tr>
                                <tr><td>DLBCL COO (N=40), n</td><td></td></tr>
                                <tr><td class="pl-4">GCB</td><td>21</td></tr>
                                <tr><td class="pl-4">Non-GCB</td><td>18</td></tr>
                                <tr><td>MYC & BCL2 Positive (DLBCL, N=40), n</td><td>8</td></tr>
                                <tr><td>Bulky Disease (≥7cm), n (%)</td><td>8 (19.0%)</td></tr>
                                <tr><td>Prior Lines of Treatment ≥3, n (%)</td><td>36 (85.7%)</td></tr>
                                <tr><td>Prior ASCT, n (%)</td><td>7 (16.7%)</td></tr>
                                <tr><td>Prior CAR T-cell Therapy, n (%)</td><td>5 (11.9%)</td></tr>
                                <tr><td>Median Glofitamab Cycles (range)</td><td>3.5 (1-11)</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (DLBCL Pts, N=36 Evaluable)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Overall Response Rate (ORR): 72.2% (26/36)</li>
                        <li>Complete Response (CR) Rate: 38.8% (14/36)</li>
                        <li>Partial Response (PR) Rate: 33.3% (12/36) (Calculated)</li>
                        <li>Burkitt's lymphoma (n=1 evaluable): PR</li>
                        <li>All CRs were ongoing at data cut-off.</li>
                        <li>Median OS and median PFS were not reached.</li>
                    </ul>
                    <div class="chart-container mb-6">
                        <svg id="glofitamabSalvageResponseChart" width="350" height="300"></svg>
                        <div id="glofitamabSalvageResponseLegend" class="legend"></div>
                    </div>
                </div>

                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=42)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Cytokine Release Syndrome (CRS): 38 (90.5%) patients.
                            <ul class="list-circle list-inside ml-4">
                                <li>Mostly Grade 1 (80.1% of all patients, calculated as 38*0.801 for specific G1 count, or 90.5% * X = G1, if 80.1% refers to proportion of CRS events. Assuming 80.1% of CRS events were G1). Abstract states "Most of the CRS events were low grade (Grade 1: 80.1%)" - this suggests 80.1% of the 90.5% were G1. Actual G1 count: 38 * 0.801 ≈ 30 patients. The remaining were G2.
                                </li>
                            </ul>
                        </li>
                        <li>Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): 3 patients.</li>
                        <li>Immune-related Myocardial Injury: 1 patient.</li>
                        <li>Most Common Grade 3/4 AE: Neutropenia (23/42; 54.8%), mainly due to combined chemotherapy.</li>
                        <li>No Grade 5 AEs reported.</li>
                        <li>No discontinuations of glofitamab-based therapy due to AEs.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Preliminary results from this prospective real-world study demonstrate the effectiveness and safety of glofitamab-based salvage therapy for heavily pre-treated R/R DLBCL patients with high-risk prognostic factors.</li>
                <li>Updated analyses, including further follow-up data and exploratory applications of glofitamab, will be presented.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ASCT, Autologous Stem-Cell Transplantation; BCL2, B-cell lymphoma 2; BsAb, Bispecific Antibody; C, Cycle; CAR, Chimeric Antigen Receptor; CD, Cluster of Differentiation; CIT, Chemoimmunotherapy; CR, Complete Response; CRS, Cytokine Release Syndrome; D, Day; DHAP, Dexamethasone, high-dose Ara-C (cytarabine), Platinol (cisplatin); DLBCL, Diffuse Large B-Cell Lymphoma; ECOG, Eastern Cooperative Oncology Group; EOT, End of Treatment; EPOCH, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; G, Grade; GCB, Germinal Center B-cell like; GemOx, Gemcitabine and Oxaliplatin; HGBCL, High-Grade B-Cell Lymphoma; ICANS, Immune effector Cell-Associated Neurotoxicity Syndrome; IPI, International Prognostic Index; IRB, Institutional Review Board; IV, Intravenous; LOT, Lines of Therapy; mg, Milligram; MYC, Myelocytomatosis oncogene; NCT, National Clinical Trial; NGS, Next-Generation Sequencing; ORR, Overall Response Rate; OS, Overall Survival; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; PR, Partial Response; R/R, Relapsed or Refractory.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Huang H, Zhou J, You T. Glofitamab combined with salvage therapy for relapsed or refractory diffuse large B cell lymphoma: A real-world prospective observational study in Chinese patients. Abstract #PS1963 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1963 | Abstract Release: 05/14/2025 | Presentation: 06/14/2025</p>
            <p>NCT06497452 | For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawGlofitamabSalvageResponseChart(containerId, legendContainerId) {
            // Data for N=36 evaluable DLBCL: ORR 72.2%, CRR 38.8%
            // PRR = ORR - CRR = 72.2 - 38.8 = 33.4%
            // Other (SD/PD/NR) = 100 - ORR = 100 - 72.2 = 27.8%
            const chartData = {
                keys: ["CR", "PR", "Other (SD/PD/NR)"],
                values: {
                    CR: 38.8,
                    PR: 33.4,
                    "Other (SD/PD/NR)": 27.8
                },
                colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
                orr: 72.2
            };
            const chartTitle = "Best Response in DLBCL (N=36 Evaluable)";

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.85, 280);
            }

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 40, right: 20, bottom: 30, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <= 0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"];
            const stack = d3.stack().keys(chartData.keys.filter(key => chartData.values[key] > 0));
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.6);

            const yScale = d3.scaleLinear()
                .domain([0, 100])
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([]))
                .select(".domain").remove();

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => Math.max(0, yScale(d[0]) - yScale(d[1])))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => {
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);

            stackedData.forEach((series) => {
                series.forEach((d) => {
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 5) {
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === 'Other (SD/PD/NR)' && percentage > 15) ? "white" : "var(--sobi-dark-text)")
                            .style("font-size", "10px")
                            .style("font-weight", "bold")
                            .text(`${percentage.toFixed(1)}%`);
                    }
                });
            });
             if (chartData.orr) {
                 g.append("text")
                    .attr("class", "chart-label orr-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 8)
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("font-size", "10px")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(1)}%`);
            }

            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.filter(key => chartData.values[key] > 0).map(key => ({
                label: `${key} (${chartData.values[key].toFixed(1)}%)`,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawChartPS1963 = debounce(() => drawGlofitamabSalvageResponseChart("#glofitamabSalvageResponseChart", "#glofitamabSalvageResponseLegend"), 250);

        window.addEventListener('resize', debouncedDrawChartPS1963);

        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawChartPS1963();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawChartPS1963, 0);
        }
    </script>
</body>
</html>